Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 816 results for "zydus cadila"

Zydus Cadila bets big on oncology

After having established a strong presence in cardiology, respiratory and other segments, pharma major Cadila Healthcare, popularly known as Zydus Cadila, is betting big on oncology and aims to become the number one in the segment by 2020. Times of India, 1 week ago
DNA

Cadila Health up 3%, Zydus to market pain killer drug in US

"The Zydus group has received the market authorisation from the US Food and Drug Administration (USFDA) to market Morphine sulphate ER tablets," said the company in its filing to the exchange.
 Money Control1 month ago Zydus gets USFDA nod to sell morphine sulfate tablets  DNA1 month ago Lupin, Cadila Health, Alembic Pharma up 1-3% on USFDA nods  Moneycontrol.com1 month ago Zydus Gets US Regulator's Nod for Pain Reliever Tablets  NDTV Profit1 month ago
[x]  
India Infoline

Cadila Healthcare gains after receiving market authorisation from USFDA for a medicine

Cadila Healthcare rose 1.29% to Rs 1,820 at 15:15 IST on BSE after the company said the Zydus group has received the market authorisation from the United States Food & Drug Administration to market Morphine Sulfate ER tablet. The company made announcement ...
 Business Standard1 month ago Zydus Cadila gets USFDA nod for Pyridostigmine Bromide tablets  Hindu Business Line1 month ago Zydus Cadila gets approval for Pyridostigmine Bromide Tablets  India Infoline1 month ago Zydus receives US FDA approval to market pyridostigmine bromide tablets  PharmaBiz1 month ago
[x]  
Bio Spectrum Asia

Zydus Cadila: A year of unparalleled growth

 Bio Spectrum Asia3 weeks ago Zydus presents new data on Lipaglyn to treat patients with type 2 diabetes at ADA scientific session in Boston  PharmaBiz1 month ago Zydus Posts New Scientific Data on Lipaglyn (Saroglitazar)  Individual.com1 month ago Zydus to Present New Scientific Data on Lipaglyn (Saroglitazar), and Real World Data in Patients With Type 2 Diabetes at the American Diabetes Association 75th Scientific Sessions in Boston, USA  Barchart1 month ago
[x]  

US CLEARS ZYDUS' NEUROLOGICAL DRUG

Ahmedabad-based Zydus Cadila has received final approval from the US Food and Drug Administration (US FDA), to market Pyridostigmine Bromide Tablets USP, 60 milligrams (mg). The tablets are used in the treatment of various neurological ...
 Pharmacy Choice1 month ago Cadila Healthcare up 3% on USFDA nod for neurological drug  Moneycontrol.com1 month ago Zydus wins USFDA nod for neurological drug  Business Standard India1 month ago Brief: Zydus wins USFDA nod for neurological drug  Smart Investor1 month ago
Times of India

Zydus Cadila 2014-15 net up 43%

Zydus Cadila registered a net profit of Rs. 1151 crores for the year ended 31st March 2015 — up by 43% from Rs. 804 crores in the previous year.
 Times of India2 months ago Zydus Cadila Q4 net up 46%; revenues jump 16%  Business Standard2 months ago
Moneycontrol.com

Cadila Healthcare to delist from Ahmedabad Stock Exchange, will remain listed on BSE and NSE

NEW DELHI: Cadila Healthcare has decided to delist its shares from Ahmedabad Stock Exchange (ASE) in view of non-trading of the company's shares on the exchange for past many years. The company's board, which met today, decided to delist equity ...
 Economic Times1 month ago Cadila to delist from Ahmedabad Stock Exchange  DeshGujarat1 month ago

Hepatitis A - Pipeline Review, H1 2015

Research and Markets (http://www.researchandmarkets.com/research/kvdhn4/hepatitis_a) has announced the addition of the "" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis A, ...
 Individual.com6 days ago Global Statin Market 2015-2019  Franklin Credit Management Corporation6 days ago Research and Markets: Global Statin Market 2015-2019 with AstraZeneca, Merck, Novartis & Pfizer Dominating  Yahoo! Finance UK and Ireland3 days ago Global Statin Market 2015-2019 with AstraZeneca, Merck, Novartis & Pfizer Dominating  Individual.com3 days ago
[x]  

Pieris Pharmaceuticals to Host Second Quarter 2015 Investor Call on August 13th

) - Pieris Pharmaceuticals, Inc . ( NASDAQ: PIRS ), a biotechnology company advancing its proprietary Anticalin ® biotherapeutic technologies, announced today that it will conduct a conference call on Thursday, August 13 at 10:00 AM (EDT) to ...
 Marketplace4 days ago Pieris Pharmaceuticals, Inc. (PIRS: null) | Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock  OTC Markets6 days ago Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock  Fat Pitch Financials6 days ago PIERIS PHARMACEUTICALS : to Host Second Quarter 2015 Investor Call on August 13th  4 Traders4 days ago
[x]  
MedIndia

Israel-Based Company Purchases Allergan's Generics Business for (Dollar) 40 Billion

Teva Pharmaceutical Industries purchases Allergan's generics business for $40.5-billion. This may help generic-drug makers to acquire products that may be divested s part of the antitrust procedures in the US and fill their portfolio gaps. Teva ...
 MedIndia5 days ago Teva-Allergan deal signals both opportunities, threats for Indian pharma  Business Today India6 days ago Teva-Allergan deal a booster for Indian companies  Economic Times1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - zydus cadila
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less